Learning Center

Your central location for online learning and education surrounding all aspects of tissue donation, tissue banking, research and transplantation.

Back to Search by Speaker

Rod Hale, MS

Rod Hale, MS

Rod is an Account Executive with VRL-Eurofins. He graduated magna cum laude from Utah State University in 1992 with a Bachelor of Science in Applied Biology. In 1997 he earned his Masters of Science in Medical and Molecular Genetics from Indiana University. He has 20 years of experience in the Human Cell & Tissue Product (HCT/P) industry. The first 12 years were spent at Laboratories At Bonfils, (which became LABS, Inc.). Rod performed various immunological and molecular tests for the screening of eye, tissue, organ, and other transplant donors, eventually becoming the manager of the Infectious Disease department, where he successfully implemented and oversaw the testing logistics that enabled the small regional lab to achieve nationwide growth. In 2010 he helped start-up the human-screening division of VRL, which has recently merged with LABS, Inc. to become the leader in HCT/P screening.

Content Where I Am Featured

Search by Format
Sort By
Search by Favorites

  • The Basics of Serology Testing for NADOs
    Contains 4 Component(s), Includes Credits

    This presentation will go over the basics of donor serology testing. This includes an explanation and comparison of the different methodologies that are used, as well as how those methodologies impact testing. We will also discuss various testing challenges, and what the donor community can do to help minimize those challenges for a mutually beneficial outcome. Finally, we’ll focus on the unique testing needs of Non-transplant Anatomical Donor Organizations.

  • The Basics of Serology Testing for NADOs (Group)
    Contains 4 Component(s), Includes Credits

    This presentation will go over the basics of donor serology testing. This includes an explanation and comparison of the different methodologies that are used, as well as how those methodologies impact testing. We will also discuss various testing challenges, and what the donor community can do to help minimize those challenges for a mutually beneficial outcome. Finally, we’ll focus on the unique testing needs of Non-transplant Anatomical Donor Organizations.